Macular Involvement in Diabetic Retinopathy Evaluated With Swept-Source OCT

Sponsor
University of British Columbia (Other)
Overall Status
Recruiting
CT.gov ID
NCT03765112
Collaborator
(none)
175
1
1
54.3
3.2

Study Details

Study Description

Brief Summary

This study evaluates micro-vascular changes in patients with diabetes. Results of diseased retinas will be compared to healthy controls.

Condition or Disease Intervention/Treatment Phase
  • Device: Optical coherence tomography angiography
N/A

Detailed Description

The prevalence of diabetes mellitus (DM) is increasing worldwide. Diabetic retinopathy is the most prevalent complication of DM and a leading cause of visual impairment due to closure of capillaries. High-resolution imaging techniques of the retina and its supplying vascular networks can allow novel insight to subtle changes that cannot be appreciated in standard fundus examination. In this study capillary changes of patients with different severity levels of diabetic retinopathy will be investigated with non-invasive imaging technology to better understand the process of disease progression.

Imaging will be done with Optical Coherence tomography (OCT) angiography as well as spectral domain OCT and ultra wide-field imaging.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
175 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Macular Involvement in Diabetic Retinopathy Evaluated With Swept-Source OCT
Actual Study Start Date :
Sep 20, 2018
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Mar 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: OCTA

Patients with diabetes and healthy controls will be imaged with optical coherence tomography (OCT) angiography, Spectral domain OCT and ultra wide-field imaging.

Device: Optical coherence tomography angiography
Multiple scans of the retina will be recorded to evaluate microvascular changes.

Outcome Measures

Primary Outcome Measures

  1. Perfusion density [6 months]

    The density of perfused capillaries (metric variable) measured with optical coherence tomography angiography (OCTA) will be compared between the different severity levels of diabetic retinopathy as well as to the control arm.

Secondary Outcome Measures

  1. Areas of different perfusion density [6 months]

    Perfusion density of the capillary network will be measured at seven different areas and will be compared within the same patient

  2. Foveal avascular zone (FAZ) [6 months]

    Size (area) of FAZ will be compared between the different severity levels of diabetic retinopathy as well as to the control arm.

  3. Foveal avascular zone (FAZ) [6 months]

    The circularity of FAZ will be compared between the different severity levels of diabetic retinopathy as well as to the control arm.

  4. Presence of predominantly peripheral lesions (PPL) [6 months]

    The presence of PPL (categorical variable yes/no) will be correlated with the perfusion density measured with OCTA

  5. Retinal layer thickness [6 months]

    Retinal layer thickness measured with optical coherence tomography (OCT) will be correlated with the perfusion density measured with OCTA

  6. Change in perfusion density in patients with moderate or severe non proliferative diabetic retinopathy (DR) or low risk proliferative DR over the follow up of one year [18 months]

    Patients with moderate or severe non proliferative diabetic retinopathy (DR) or low risk proliferative DR will be followed over one year. Perfusion density will be measured at each timepoint and followed over the year,

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age ≥18 Participants can have 1 or 2 study eyes
Patient Group:
  • Diabetes mellitus type 1 or 2

  • Study eye with any DR severity level: no DR, mild NPDR, mod NPDR, sev NPDR, PDR

Exclusion Criteria:
  • Substantial media opacities that would preclude successful imaging

  • Active intraocular inflammation (grade trace or above) in either eye like infectious conjunctivitis, keratitis, scleritis, endophthalmitis as well as idiopathic or autoimmune-associated uveitis in either eye

  • Structural damage to the center of macula in the study eye

  • History of prior panretinal photocoagulation

  • History of treatment with intravitreal agents over the prior 6 months

  • Macular edema involving the central subfield

  • Prior history of vitrectomy

  • Atrophy of retinal pigment epithelium, subretinal fibrosis, laser scar within foveal avascular zone (FAZ) or organized hard exudate plaques

  • Substantial non-diabetic intraocular pathology in the study eye including retinal vascular occlusion, retinal detachment, macular hole, choroidal neovascularization, macula dystrophies

  • Intraocular surgery (including cataract surgery, YAG laser capsulotomy) in the study eye within 3 months preceding Day 0, or history of corneal transplantation in the study eye

  • Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma medication)or history of glaucoma filtration surgery

  • Inability to obtain fundus images of sufficient quality to be analyzed and graded

Contacts and Locations

Locations

Site City State Country Postal Code
1 Eye Care Center Vancouver Canada V5Z 3N9

Sponsors and Collaborators

  • University of British Columbia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eduardo Navajas, Principal Investigator, University of British Columbia
ClinicalTrials.gov Identifier:
NCT03765112
Other Study ID Numbers:
  • H18-02095
First Posted:
Dec 5, 2018
Last Update Posted:
Oct 1, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 1, 2021